VanEck Pharmaceutical ETF (NASDAQ:PPH) Sees Large Volume Increase – Here’s What Happened

Shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) saw an uptick in trading volume on Friday . 178,773 shares changed hands during mid-day trading, an increase of 44% from the previous session’s volume of 123,941 shares.The stock last traded at $86.75 and had previously closed at $86.34.

VanEck Pharmaceutical ETF Trading Up 0.5 %

The stock has a market cap of $641.16 million, a PE ratio of 21.04 and a beta of 0.72. The business’s 50-day moving average price is $88.98 and its 200-day moving average price is $92.56.

VanEck Pharmaceutical ETF Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 27th were given a $0.411 dividend. This is a positive change from VanEck Pharmaceutical ETF’s previous dividend of $0.36. The ex-dividend date was Friday, December 27th.

Hedge Funds Weigh In On VanEck Pharmaceutical ETF

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in VanEck Pharmaceutical ETF by 12.5% during the third quarter. FMR LLC now owns 1,905 shares of the company’s stock valued at $181,000 after purchasing an additional 212 shares during the period. Edge Financial Advisors LLC acquired a new position in shares of VanEck Pharmaceutical ETF in the 3rd quarter valued at about $263,000. Harbour Investments Inc. boosted its stake in shares of VanEck Pharmaceutical ETF by 16.6% in the third quarter. Harbour Investments Inc. now owns 3,425 shares of the company’s stock worth $325,000 after buying an additional 488 shares during the last quarter. Townsquare Capital LLC grew its holdings in VanEck Pharmaceutical ETF by 3.8% during the third quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock worth $334,000 after acquiring an additional 130 shares during the period. Finally, Assetmark Inc. boosted its position in VanEck Pharmaceutical ETF by 5.8% in the 3rd quarter. Assetmark Inc. now owns 6,491 shares of the company’s stock worth $617,000 after purchasing an additional 354 shares in the last quarter.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.